Skip to content

Privia Health

US · PRVA #2604 by market cap Listed 2021
25.05 +0.36 +1.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 3.85 Cheap vs history 20th percentile
5-year average 5.06 · #25 of 37 in Health Information Services
P/E ratio 94.42 In line with history 43rd percentile
5-year average 80.22 · forward 50.22 · #15 of 16 in Health Information Services
P/S ratio 1.29 Cheap vs history 15th percentile
5-year average 1.88 · forward 1.16 · #17 of 41 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
Privia Health (PRVA) 3.20B 96.35 3.92 0.00%
Veeva Systems (VEEV) 43.10B 43.64 5.80 0.00%
BrightSpring Health Services (BTSG) 12.50B 33.78 5.75 0.00%
Tempus AI (TEM) 9.86B -50.98 19.70 0.00%
Hinge Health (HNGE) 8.60B 51.68 28.71 0.00%
HealthEquity (HQY) 7.84B 34.21 3.94 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value26.41 Economic moatNarrow UncertaintyMedium

Trading 5.4% below Morningstar's fair value estimate.

Fair value

Privia Health Group Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $26.41 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's valuation metrics increase our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 7.0 lies in the top 50% compared with peers globally. While the liquidation value can be important for some businesses, we don't believe this is one of them. The low cash balance relative to the firm's market value could signal heavy reinvestment for growth. We believe this is a sign that shares could be cheap.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 2.4%, for example, ranks in the bottom 40% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Privia Health discussion 0 comments

Add a comment